80S Ribosome
Protein nucleic-acid complex in Homo sapiens that 9 drugs act on.
- Drugs that act on it: 9
- Approved: 1
- In phases 1 to 3: 8
- Sponsors: 5
- Genes: 81
Who is on it, and how far along
Every drug ChEMBL records acting on FAU, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 2
- Antibody-drug conjugate 5
- Other 2
Approved1
Phase 30
Phase 28
Phase 10
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Eloxx Pharmaceuticals, Inc.111%
- Molecular Templates111%
- PTC Therapeutics111%
- Sesen Bio, Inc.111%
- Tasly Tianjin Biopharmaceutical Co., Ltd.111%
| Ataluren | Approved | PTC Therapeutics | Small molecule | Modulator80S Ribosome modulator | 1 |
| Cycloheximide | Phase 2 | — | Small molecule | Inhibitor | 2 |
| Citatuzumab bogatox | Phase 2 | Sesen Bio, Inc. | Antibody-drug conjugate | Inhibitor | 0 |
| Dorlimomab aritox | Phase 2 | — | Antibody-drug conjugate | Inhibitor | 0 |
| ELX-02 | Phase 2 | Eloxx Pharmaceuticals, Inc. | Other | Modulator80S Ribosome modulator | 0 |
| MT-3724 | Phase 2 | Molecular Templates | Other | Inhibitor | 0 |
| Taplitumomab paptox | Phase 2 | — | Antibody-drug conjugate | Inhibitor | 0 |
| Telimomab aritox | Phase 2 | Tasly Tianjin Biopharmaceutical Co., Ltd. | Antibody-drug conjugate | Inhibitor | 0 |
| Zolimomab aritox | Phase 2 | — | Antibody-drug conjugate | Inhibitor | 0 |
| Clinical, Dermoscopic, and Mycological Characteristics of Tinea Capitis in Children | Cycloheximide | — | Not yet recruiting | Sohag University | Sep 3, 2026 |
| Clinical, Dermoscopic, and Mycological Evaluations of Resistant Dermatophytosis | Cycloheximide | — | Not yet recruiting | Sohag University | Sep 1, 2026 |
| Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study | Ataluren | Phase 1 / Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Jul 10, 2019 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3987582, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets